Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma (NCT00006119) | Clinical Trial Compass
CompletedPhase 2
Hydroxyurea in Treating Patients With Recurrent and/or Unresectable Meningioma
FranceStarted 1999-07
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of hydroxyurea in treating patients who have recurrent and/or unresectable meningioma.
Who can participate
Age range16 Years – 120 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically proven progressive meningioma that is not curable by surgery
PATIENT CHARACTERISTICS:
Age:
* 16 and over
Performance status:
* Karnofsky 70-100%
Life expectancy:
* Over 3 months
Hematopoietic:
* WBC at least 3,000/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic:
* Bilirubin no greater than 2 times upper limit of normal (ULN)
* AST and ALT no greater than 2 times ULN
* Alkaline phosphatase no greater than 2 times ULN
Renal:
* Creatinine no greater than 2 times ULN
Other:
* Not pregnant or nursing
* Fertile patients must use effective contraception during and for 6 months after study
* No other malignancy
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
* No other concurrent chemotherapy
Endocrine therapy:
* Concurrent corticosteroids allowed for control of intracranial pressure
Radiotherapy:
* Prior radiotherapy allowed
* No concurrent radiotherapy
Surgery:
* See Disease Characteristics
Other:
* At least 1 year since prior experimental therapy